Non-opioid CNS pipeline: SBS-147 oral AEAr agonist Phase 1 (RA), SBS-226 OUD dual receptor, SBS-518 stimulant addiction; ~$75M non-dilutive backing across 5 NIH/NIDA grants
No detailed funding rounds available.
Total known funding: